Drug Approval | June 13, 2025
FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Subscribe To Our Newsletter & Stay Updated
